Press Releases
- Active Biotech AB Interim report January - September 2012 November 9, 2012 08:30 (CET)
- PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA FOR POTENTIAL USE IN ACTIVE CROHN'S DISEASE October 22, 2012 15:00 (CEST)
- Active Biotech's partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications October 19, 2012 07:15 (CEST)
- Ipsen initiates a phase II "Switch maintenance" trial in metastatic castrate-resistant prostate cancer with tasquinimod October 3, 2012 18:30 (CEST)
- Tasquinimod Biomarker Phase II data presented at ESMO 2012 October 1, 2012 08:30 (CEST)
- Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference September 6, 2012 08:30 (CEST)
- Active Biotech AB Interim report January - June 2012 August 10, 2012 08:30 (CEST)
- TEVA TO INITIATE THIRD PHASE III TRIAL OF ORAL LAQUINIMOD FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS August 8, 2012 14:00 (CEST)
- ACTIVE BIOTECH ANNOUNCE THAT EUROPEAN MEDICINES AGENCY ACCEPTS START OF SCIENTIFIC REVIEW OF THE MARKETING AUTHORIZATION APPLICATION FOR LAQUINIMOD IN RELAPSING-REMITTING MULTIPLE SCLEROSIS July 17, 2012 08:30 (CEST)
- Active Biotech's and Ipsen's Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer June 4, 2012 15:00 (CEST)